Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Multiple Sclerosis (Feb 2020)

Posted by Matt Breese on Feb 7, 2020

Find me on:

According to our recent payer coverage analysis for multiple sclerosis treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for multiple sclerosis treatments shows that under the pharmacy benefit, about half of the lives under commercial formularies are covered with utilization management restrictions.

MMIT-Reality Check-Multiple Sclerosis-1Q2020Data snapshot as of Q1 2020

Trends: In October 2019, the FDA approved Biogen Inc. and Alkermes plc’s Vumerity (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsingremitting disease and active secondary progressive disease.  

To read the full Reality Check on Multiple Sclerosis treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing